To improve security and privacy, we are moving our web pages and services from HTTP to HTTPS.
To give users of web services time to transition to HTTPS, we will support separate HTTP and HTTPS services until the end of 2017.
From January 2018 most HTTP traffic will be automatically redirected to HTTPS. [more...]
View this page in https

UniProtKB/Swiss-Prot O97980: Variant p.His16Tyr

Minor histocompatibility protein HB-1
Gene: HMHB1
Chromosomal location: 5q32
Variant information

Variant position:  16
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Histidine (H) to Tyrosine (Y) at position 16 (H16Y, p.His16Tyr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (H) to large size and aromatic (Y)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In allele HB-1Y; loss of CTL recognition for epitope HB-1. No influence on HLA-B/HLA-B44 binding, nor on the processing by the proteasome.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  16
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  41
The length of the canonical sequence.

Location on the sequence:   MEEQPECREEKRGSL  H VWKSELVEVEDDVYLRHSSS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 41 Minor histocompatibility protein HB-1
Peptide 9 – 18 Minor histocompatibility antigen HB-1
Region 9 – 17 Loss of recognition by cytotoxic T lymphocyte (CTL)
Mutagenesis 9 – 9 E -> A. Decreased CTL recognition.
Mutagenesis 10 – 10 E -> A. Decreased CTL recognition.
Mutagenesis 11 – 11 K -> A. Complete loss of CTL recognition.
Mutagenesis 12 – 12 R -> A. Complete loss of CTL recognition.
Mutagenesis 13 – 13 G -> A. Complete loss of CTL recognition.
Mutagenesis 14 – 14 S -> A. Complete loss of CTL recognition.
Mutagenesis 15 – 15 L -> A. Complete loss of CTL recognition.
Mutagenesis 16 – 16 H -> A. Complete loss of CTL recognition.
Mutagenesis 16 – 16 H -> R. CTL recognition.
Mutagenesis 17 – 17 V -> A. Decreased CTL recognition.
Mutagenesis 18 – 18 W -> A. Complete loss of CTL recognition.


Literature citations

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.
Dolstra H.; Fredrix H.; Maas F.; Coulie P.G.; Brasseur F.; Mensink E.; Adema G.J.; de Witte T.M.; Figdor C.G.; van de Wiel-van Kemenade E.;
J. Exp. Med. 189:301-308(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; PROTEIN SEQUENCE OF 9-18; TISSUE SPECIFICITY; FUNCTION; VARIANT TYR-16;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.